Characteristics | Total (n = 187) | MACC1 tumor center N (%); (n = 187) | P-value | |
---|---|---|---|---|
 |  | Low (Score 0) | High (Score 1–3) |  |
 |  | N = 78 (41.7%) | N = 109 (58.3%) |  |
Age (yrs.) | ||||
Mean (min, max) | 68.6 (35–93) | 69.2 (36–93) | 68.1 (35–91) | 0.1732 |
Tumor size (cm) | ||||
Mean (min, max) | 4.5 (1.2–12) | 4.8 (2–12) | 4.3 (1.2–8) | 0.5723 |
Gender | Â | Â | Â | Â |
Male | 88 (47.3) | 35 (44.9) | 53 (49.1) | 0.5711 |
Female | 98 (52.7) | 43 (55.1) | 55 (50.9) | Â |
Histological subtype | ||||
Non-mucinous | 167 (89.3) | 70 (89.7) | 97 (89.0) | 0.8695 |
Mucinous | 20 (10.7) | 8 (10.3) | 12 (11.0) | Â |
Tumor grade | ||||
G1-2 | 120 (64.2) | 55 (70.5) | 65 (59.6) | 0.126 |
G3 | 67 (35.8) | 23 (29.5) | 44 (40.4) | Â |
Tumor location | ||||
Left | 113 (60.7) | 42 (53.9) | 71 (65.7) | 0.2027 |
Rectum | 21 (11.3) | 9 (11.5) | 12 (11.1) | Â |
Right | 52 (28.0) | 27 (34.6) | 25 (23.2) | Â |
pT | ||||
pT1 + pT2 | 47 (25.1) | 26 (33.3) | 21 (19.3) | 0.0288 |
pT3 + pT4 | 140 (74.9) | 52 (66.7) | 88 (80.7) |  |
pN | ||||
pN0 | 97 (51.9) | 51 (65.4) | 46 (42.2) | 0.0018 |
pN1-2 | 90 (48.1) | 27 (34.6) | 63 (57.8) | Â |
pM | ||||
pM0 | 167 (89.8) | 73 (93.6) | 94 (87.0) | 0.1454 |
pM1 | 19 (10.2) | 5 (6.4) | 14 (13.0) | Â |
TNM stage | ||||
Stage I | 40 (21.5) | 26 (33.3) | 14 (13.0) | 0.0023 |
Stage II | 53 (28.5) | 24 (30.8) | 29 (26.9) | Â |
Stage III | 74 (39.8) | 23 (29.5) | 51 (47.2) | Â |
Stage IV | 19 (10.2) | 5 (6.4) | 14 (13.0) | Â |
Tumor budding | ||||
Low-grade | 101 (54.0) | 54 (69.2) | 47 (43.1) | 0.0004 |
High-grade | 86 (46.0) | 24 (30.8) | 62 (56.9) | Â |
Venous invasion | ||||
Present | 32 (17.1) | 8 (10.3) | 24 (22.0) | 0.0352 |
Absent | 155 (82.9) | 70 (89.7) | 85 (78.0) | Â |
Lymphatic invasion | ||||
Present | 74 (39.6) | 24 (30.8) | 50 (45.9) | 0.0373 |
Absent | 113 (60.4) | 54 (69.2) | 59 (54.1) | Â |
Therapy | ||||
Untreated | 66 (35.3) | 39 (50.0) | 27 (24.8) | 0.0004 |
Treated | 121 (64.7) | 39 (50.0) | 82 (75.2) | Â |
MMR status | ||||
Proficient | 170 (91.4) | 71 (91.0) | 99 (91.7) | 0.8777 |
Deficient | 16 (8.6) | 7 (9.0) | 9 (8.3) | Â |
KRAS status | ||||
Wild-type | 124 (67.0) | 54 (70.1) | 70 (64.8) | 0.4484 |
Mutation | 61 (33.0) | 23 (29.9) | 38 (35.2) | Â |
BRAF status | ||||
Wild-type | 165 (91.2) | 69 (92.0) | 96 (90.6) | 0.7378 |
Mutation | 16 (8.8) | 6 (8.0) | 10 (9.4) | Â |
CIMP status | ||||
Negative/Low | 90 (87.4) | 40 (90.9) | 50 (84.8) | 0.3887 |
High | 13 (12.6) | 4 (9.1) | 9 (15.3) | Â |
Survival rate | ||||
Median | 60 (50-ne) | Not reached | 58 (43-ne) | 0.2585 |